Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
JACC Cardiovasc Interv. 2018 Sep 24;11(18):1824-1833. doi: 10.1016/j.jcin.2018.06.030.
This study sought to examine whether quality improvement initiatives across multiple ST-segment elevation myocardial infarction (STEMI) systems translated to faster first medical contact (FMC)-to-device times for patients presenting with cardiogenic shock (CS).
There are limited data describing contemporary rates of achieving guideline-directed FMC-to-device times for STEMI patients with CS.
From 2012 to 2014, the American Heart Association Mission: Lifeline STEMI Systems Accelerator project established a protocol-guided approach to STEMI reperfusion systems in 484 U.S. hospitals. The study was stratified by CS versus no CS at presentation and performed Cochrane-Armitage tests to evaluate trends of achieving FMC-to-device time targets. A multivariable logistic regression model assessed the association between achieving guideline-directed FMC-to-device times and mortality.
Among 23,785 STEMI patients, 1,993 (8.4%) experienced CS at presentation. For direct presenters, patients with CS were less likely to achieve the 90-min FMC-to-device time compared with no-CS patients (37% vs. 54%; p < 0.001). For transferred patients, CS patients were even less likely to reach the 120-min FMC-to-device time compared with no-CS patients (34% vs. 47%; p < 0.0001). The Accelerator intervention did not result in improvements in the FMC-to-device times for direct-presenting CS patients (p for trend = 0.53), although there was an improvement for transferred patients (p for trend = 0.04). Direct-presenting patients arriving within 90 min had lower mortality rates compared with patients who reached after 90 min (20.49% vs. 39.12%; p < 0.001).
Fewer than 40% of STEMI patients presenting with CS achieved guideline-directed FMC-to-device targets; delays in reperfusion for direct-presenting patients were associated with higher mortality.
本研究旨在探讨在多个 ST 段抬高型心肌梗死(STEMI)系统中实施质量改进措施是否能缩短出现心源性休克(CS)的患者从首次医疗接触(FMC)到接受器械治疗的时间。
目前,有关达到心源性休克的 STEMI 患者指南指导的 FMC 到器械时间的最新数据有限。
2012 年至 2014 年,美国心脏协会使命:生命线 STEMI 系统加速器项目在美国 484 家医院建立了一种基于协议的 STEMI 再灌注系统方法。本研究根据患者就诊时是否出现 CS 进行分层,并进行 Cochrane-Armitage 检验以评估达到 FMC 到器械时间目标的趋势。多变量逻辑回归模型评估了达到指南指导的 FMC 到器械时间与死亡率之间的关联。
在 23785 例 STEMI 患者中,有 1993 例(8.4%)就诊时出现 CS。对于直接就诊者,与无 CS 患者相比,CS 患者更不可能达到 90 分钟的 FMC 到器械时间(37%比 54%;p<0.001)。对于转院患者,与无 CS 患者相比,CS 患者甚至更不可能达到 120 分钟的 FMC 到器械时间(34%比 47%;p<0.0001)。尽管对于转院患者,加速器干预确实改善了 FMC 到器械时间(趋势检验 p 值=0.04),但对于直接就诊的 CS 患者,该干预并未改善 FMC 到器械时间(趋势检验 p 值=0.53)。在 90 分钟内到达的直接就诊患者的死亡率低于 90 分钟后到达的患者(20.49%比 39.12%;p<0.001)。
不到 40%的出现 CS 的 STEMI 患者达到了指南指导的 FMC 到器械目标;直接就诊患者的再灌注延迟与更高的死亡率相关。